Abstract
The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.
Keywords: HCQ, diabetes mellitus, COVID-19, T2DM, vaccine, pandemic, SARS-CoV-2.
Infectious Disorders - Drug Targets
Title:COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail
Volume: 21 Issue: 5
Author(s): Rimesh Pal, Manoj K. Bhasin and Sanjay K. Bhadada*
Affiliation:
- Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012,India
Keywords: HCQ, diabetes mellitus, COVID-19, T2DM, vaccine, pandemic, SARS-CoV-2.
Abstract: The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.
Export Options
About this article
Cite this article as:
Pal Rimesh , Bhasin K. Manoj and Bhadada K. Sanjay *, COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail, Infectious Disorders - Drug Targets 2021; 21 (5) : e270421186842 . https://dx.doi.org/10.2174/1871526520666201013160803
DOI https://dx.doi.org/10.2174/1871526520666201013160803 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
Call for Papers in Thematic Issues
New Frontiers in Infectious Disease Research: Small-Molecule Probes and Biomarker Identification
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adipose-Derived Factors During Nutritional Transitions
Current Nutrition & Food Science Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Current Pharmaceutical Design Increased Paternal Age and Child Health and Development
Current Pediatric Reviews From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Schistosoma mansoni Antigens as Modulators of the Allergic Inflammatory Response in Asthma
Endocrine, Metabolic & Immune Disorders - Drug Targets Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Management of Osteoporosis: Seeing the Future
Medicinal Chemistry Reviews - Online (Discontinued) Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer
Mini-Reviews in Medicinal Chemistry Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews